Alteration in mean platelet volume and platicrit values in patients with cancer that developed thrombosis

Clinical and Applied Thrombosis/Hemostasis

Volumn 19, Issue 3, 2013, Pages 331-333

  Mutlu, Hasan ^a   Artiş, Tarik A ^b   Erden, Abdülsamet ^a   Akca, Zeki ^c  

^a Kayseri Training and Research Hospital ^*  (Turkey)

^b ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^c Mersin Government Hospital   (Turkey)

Author keywords

deep venous thrombosis; thrombosis; thrombosis prophylaxis

Indexed keywords

ADULT; AGED; ARTERIAL THROMBOEMBOLISM; ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; LUNG CANCER; MALE; MEAN PLATELET VOLUME; NEOPLASM; PLATICRIT VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTE VOLUME; VEIN THROMBOSIS;

DEEP VENOUS THROMBOSIS; THROMBOSIS; THROMBOSIS PROPHYLAXIS;

ADULT; AGED; BLOOD PLATELETS; FEMALE; HUMANS; MALE; MEAN PLATELET VOLUME; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; THROMBOSIS;

EID: 84878865132     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029611433644     Document Type: Article

References (21)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999 ; 340 (2). 115-126
2. Greisenegger S, Endler G, Hsieh K, Tentschert S, Mannhalter C, Lalouschek W. Is elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events?. Stroke. 2004 ; 35 (7). 1688-1691
3. Smith NM, Pathansali R, Bath PM. Platelets and stroke. Vasc Med. 1999 ; 4 (3). 165-172
4. Endler G, Klimesch A, Sunder-Plassmann H, et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol. 2002 ; 117 (2). 399-404
5. O'Malley T, Langhorne P, Elton RA, Stewart C. Platelet size in stroke patients. Stroke. 1995 ; 26 (6). 995-999
6. Varol E, Uysal BA, Ozaydin M. Platelet indices in patients with pulmonary arterial hypertension. Clin Appl Thromb Hemost. 2011 ;:
7. Tschoepe D, Esser J, Schwippert B, et al. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost. 1991 ; 17 (4). 433-439
8. Turhan O, Coban E, Inan D, Yalcin AN. Increased mean platelet volume in chronic hepatitis B patients with inactive disease. Med Sci Monit. 2010 ; 16 (4). CR202 - CR205
9. Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis. 1996 ; 7 (2). 157-161
10. Goldenberg N, Kahn SR, Solymoss S. Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism. J Clin Oncol. 2003 ; 21 (22). 4194-4199
11. Maraveyas A, Johnson M. Does clinical method mask significant VTE-related mortality and morbidity in malignant disease?. Br J Cancer. 2009 ; 100 (12). 1837-1841
12. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999 ; 78 (5). 285-291
13. Streiff MB. Anticoagulation in the management of venous thromboembolism in the cancer patient. J Thromb Thrombolysis. 2011 ; 31 ((3)). 282-294
14. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000 ; 160 (6). 809-815
15. Adess M, Eisner R, Nand S, Godwin J, Messmore HL, Wehrmacher WH. Thromboembolism in cancer patients: pathogenesis and treatment. Clin Appl Thromb Hemost. 2006 ; 12 (3). 254-266
16. Lee AYY, Khorana AA Cancer Principles & Practice Oncology. 8 th ed. 2008; 2634. DeVita VT Lawrence TS Rosenberg SA, ed. 2008: 2634.
17. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006 ; 166 (4). 458
18. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005 ; 293 (6). 715-722
19. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med. 2008 ; 168 (21). 2377-2381
20. Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol. 2010 ; 49 (3). 287-297
21. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007 ; 99 (16). 1232-1239